Press releases
- Cybin Announces Additional Adelia Milestone Achievement
- Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
- Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
- Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
- Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
- Cybin Acquires DMT Clinical Study from Entheon Biomedical
- Cybin Announces Additional Adelia Milestone Achievements
- Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
- Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
- Cybin to Host Key Opinion Leader Webinar on June 9, 2022
More ▼
Key statistics
On Friday, Cybin Inc (R7E1:MUN) closed at 0.5484, 37.13% above the 52 week low of 0.3999 set on May 17, 2022.
52-week range
Markit short selling activity
Open | 0.5484 |
---|---|
High | 0.5484 |
Low | 0.5484 |
Bid | -- |
Offer | -- |
Previous close | 0.5484 |
Average volume | 0.00 |
---|---|
Shares outstanding | 166.02m |
Free float | 119.37m |
P/E (TTM) | -- |
Market cap | 119.53m CAD |
EPS (TTM) | -0.4038 CAD |
Data delayed at least 15 minutes, as of Jul 01 2022 07:02 BST.
More ▼